San Francisco Bay Area biotech stories.
Thursday, August 30, 2012
Bayer submits 'son of Nexavar' cancer drug for FDA approval
Onyx CEO Tony Coles.
Bayer HealthCare Pharmaceuticals
Inc.'s experimental cancer drug regorafenib -- viewed as the "son of Nexavar" from Bayer and
Onyx Pharmaceuticals Inc.
-- was submitted Thursday for approval to the Food and Drug Administration, the companies said
. Bayer said the new drug application was submitted for regorafenib's treatment of metastatic or unresectable gastrointestinal stromal tumors in patients whose cancer continues despite prior treatments.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)